发明名称 |
DENDRITIC CELL BASED CANCER MEDICINE USING M. TUBERCULOSIS RV0652 PROTEIN AS AN ADJUVANT |
摘要 |
PURPOSE: A dendritic cell cancer therapeutic agent using M. tuberculosis Rv0652 is provided to effectively suppress tumor growth. CONSTITUTION: A dendritic cell cancer therapeutic agent is manufactured by adding M. tuberculosis Rv0652 to immature dendritic cells. Rv0652 is recombinant Rv0652(rEC-Rv0652) expressed in E.coli. The recombinant Rv0652 is produced by amplifying with a forward primer of sequence number 1 and a reverse primer of sequence number 2. The dendritic cell cancer therapeutic agent is prepared by culturing Rv0652 for 20-30 hours.
|
申请公布号 |
KR20120089050(A) |
申请公布日期 |
2012.08.09 |
申请号 |
KR20110010165 |
申请日期 |
2011.02.01 |
申请人 |
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) |
发明人 |
SHIN, SUNG JAE;JUNG, IN DUK;PARK, YEONG MIN;KIM, HWA JUNG |
分类号 |
A61K39/39;A61K38/10;A61P35/00 |
主分类号 |
A61K39/39 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|